Bio21 Big Picture Seminar: Alternative Drug Discovery in Pharma...a snapshot of diversity in GSK drug discovery through collaboration

Friday, 26 August, 2016 - 13:15

What: Bio21 Big Picture Seminar: 'Alternative Drug Discovery in Pharma...a snapshot of diversity in GSK drug discovery through collaboration'

Who: John Haselden, VP and Head of Malaria Discovery GSK

When: 12-1pm, Tuesday, 27th September, followed by refreshments in the atrium

Where: Bio21 Molecular Science and Biotechnology Institute Auditorium, David Penington Building, 30 Flemington Road, Parkville 3010

RSVP: Please follow this link to register through Survey Monkey

Event enquiries: florienne.loder [at] (Email the Bio21 External Relations Officer) or phone 9035 3015


John Haselden, VP and Head of Malaria Discovery GSK will look at a number of examples from GSK’s 'alternative' portfolio (including Diseases of the Developing World, Maternal/Neonatal Health) covering emerging drugs in discovery and some that are progressing clinically, many (if not all) of which are driven through collaboration. He will also highlight GSK's focus on 'Discovery partnership and academic collaborations' and the opportunities this can provide.

About the speaker:

John Haselden PhD FRSC FBTS

Since 2014 John has been the VP and Head of the Malaria Discovery Performance Unit (DPU) for GSK R&D, based in Spain. This unit is at the forefront of pharmaceutical engagement in the field of malaria, and is part of the Disease of the Developing World Research facility based near Madrid. Across these neglected diseases, GSK leads the way in its innovative approach to sharing of data, access to compound libraries and its openness around IP issues.

John joined Wellcome as a toxicologist in the early 90s after completing his PhD in lipid biochemistry at London (now Imperial). In 2000 he became the Director of Investigative Toxicology and as a project manager, accumulated extensive drug development expertise across a number of therapeutic areas (biopharm, GI, neurosciences, respiratory, infectious diseases).

Until 2008 John was responsible for the evaluation of metabolomic platforms within GSK and built an extensive network with the KOLs in this field. Furthermore he has served on numerous editorial and advisory boards – many in relation to Euro-centric projects on metabolomics and biomarker research, has held various visiting lecturer positions in the UK, and is currently a Visiting Professor in Biomolecular Medicine at Imperial College.